User blocked from platform after policy breach

When Nicole Schulz was a freshman in high school, a diagnosis of acute myeloid leukemia (AML) felt like a death sentence, but the care she received at City of Hope shifted her outlook and set the stage for a two‑decade battle with the disease.

Early shock and the impact of attitude

At 14, Schulz recalled hearing “you have cancer” and instantly believing her life was over. She had never known anyone who survived the illness, so the words carried an absolute finality.

The nurses moved her from the outpatient clinic to an inpatient unit within hours, treating her with a tone that suggested she could fight back. “They didn’t look at me like I was a dying kid,” she said, noting that the staff’s confidence helped her reject the notion of inevitable death.

The shift in how she was addressed made her aware of what she needed from adults but couldn’t articulate. When family and visitors expressed sympathy, she felt the words reinforced her fear. In contrast, the medical team’s belief in her ability to survive sparked a resolve she had not known she possessed.

Intensive treatment and prolonged hospitalization

Schulz’s first bone marrow transplant in 2005 required full‑body radiation, a practice that has since been discontinued. The procedure, combined with the transplant, led to an 11‑month continuous hospital stay, during which she never left the facility. “My life stopped, but the rest of the world outside kept going,” she recalled, describing the isolation as the hardest part of her treatment.

When she underwent a second transplant a few years later, advances in therapy gave her renewed hope. Previously, the outlook for a second AML relapse was bleak; the chance of survival was considered negligible. Seeing how quickly treatment protocols had evolved eased her fear and reinforced her determination to continue fighting.

It is reasonable to expect that the emotional resilience cultivated during such an extended stay will continue to influence her outlook, even as she transitions to routine follow‑up care. The combination of early optimism from staff and later improvements in AML therapy likely contributed to her long‑term survival, suggesting that patient morale and evolving treatment standards can intersect to shape outcomes.